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Abstract
Background: Adenoviral vectors have provided effective methods for in vivo gene delivery in therapeutic
applications. However, these vectors can induce immune responses that may severely affect the ability of vector re-
application. There is limited information about the mechanisms and signal transduction pathways involved in
adenoviral recognition. For optimization of cutaneous gene therapy it is necessary to investigate molecular
mechanisms of virus recognition in epidermal cells. The aim of this study was to investigate the signal transduction
of the innate immunity after adenoviral DNA internalization in keratinocytes.
Methods: In vitro, keratinocytes were transfected with DNA, in the presence and absence of inhibitors for
signalling molecules. In vivo, immunocompetent and athymic mice (n = 3 per group) were twice transduced with
an Ad-vector.
Results: The results show an acute induction of type-I-interferon after in vitro transfection. Inhibition of PI3K, p38
MAPK, JNK and NFkappaB resulted in a decreased expression of type-I-interferon. In contrast to immunocompetent
mice, athymic mice demonstrated a constant transgene expression and reduced inflammatory response in vivo.
Conclusion: The results suggest an induction of the innate immunity triggered by cytoplasm localised DNA which
is mediated by PI3K-, p38 MAPK-, JNK-, NFkappaB-, JAK/STAT- and ERK1/2-dependent pathways. A stable transgene
expression and a reduced inflammatory response in immunodeficient mice have been observed. These results
provide potential for an effective adenoviral gene delivery into immunosupressed skin.
Background
The skin is the largest organ of the body, accounting for
about fifteen percent of our body weight, and covering
the entire external surface. While many believe its role is
merely as an external covering, the functions of the skin
are far more complex. The skin consists of three main
layers - the epidermis, the dermis, and the hypodermis,
each with their own function. It is the epidermis, which
creates a barrier to and protects from pathogens of the
outside world. This highly specialised layer is mainly
composed of keratinocytes, melanocytes and dendritic
cells. Its accessibility and specific anatomical and
biological properties make the skin a very interesting
organ for in vivo and ex vivo gene therapy approaches. In
case of cutaneous gene therapy, gene delivery can be
easily controlled and the skin surgically excised if any
side effects occur [1-3].
Keratinocytes, the predominant epidermal cell type,
are responsible for establishing a physical barrier and
guaranteeing the structural integrity of the epidermis
[3]. As the epidermis is known to produce a variety of
cytokines and growth factors, keratinocytes may also be
engineered as bioreactors to secrete gene products
which have local or systemic effects [4,5].
In most gene therapy applications, a “normal” gene is
inserted into the genome of an individuals cell or tissue
to replace an “abnormal” disease-causing gene. In addi-
tion, foreign, therapeutical active genes can be intro-
duced in order to add any not normally in the body
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a promising tool for the treatment of a wide variety of
inherited as well as acquired disease including geneti-
cally inherited skin disorders, tumours, metabolic disor-
ders and infectious diseases (e.g. epidermolysis bullosa,
xeroderma pigmentosum, ichtyosis, porphyria, squamous
cell carcinomas) [6-9].
Different methods for gene delivery can be pursued,
depending on the desired application. The approach
used to deliver DNA into the skin will have an influence
not only on the efficiency of DNA delivery, but also on
the level and duration of transgene expression [10,11].
A carrier molecule called vector must be used to deli-
ver the therapeutic gene to the target cells. Based on
viral and non-viral vectors, different applications for
gene delivery have been developed in the last decades
[12,13]. For transient transduction of target cells, adeno-
viral vector systems possess the highest effectivity and
have been used in 23.9% of the official agency sources
(Gene Therapy Advisory Committee (GTAC), Recombi-
nant DNA Advisory Committee (RAC), etc.) registered
clinical trials of gene therapeutical applications for dif-
ferent indications, such as cancer, infectious or mono-
genic diseases worldwide in the last two decades [14].
Adenoviridae are non-enveloped, double stranded (ds),
linear desoxyribonucleic acid (DNA) viruses with a gen-
ome of 35-40 kb and a particle size of 70-100 nm
[15,16]. The adenoviral genome is well characterised
and comparatively easy to manipulate. Most adeno-
viruses cause mild diseases in immunocompetent
human adults and by deletion of crucial regions of the
viral genome the vectors can be rendered replication-
defective, which increases their predictability and
reduces unwanted side effects. Moreover, deleted
regions of the viral genome can easily be replaced by
foreign genomic material encoding the therapeutical
active metabolite [17].
The process of adenoviral entry into the host is extre-
mely efficient and has been intensively studied. Adeno-
viruses exhibit a wide host range in vitro and in vivo;
this range was also seen in nondividing cells [18]. In
addition, the well-defined and easily manipulated viral
genome favours the development of adenoviral vectors
for gene therapy applications [19]. This, together with
information from the complete library of human DNA
opened up extensive opportunities for gene therapy in
medical and surgical specialities [20].
The major disadvantage of adenoviral vectors is that
they can effectively induce the adaptive and innate
immune response immediately after infection, leading to
an induction of proinflammatory cytokines and chemo-
kines in mice, primates and humans [21-23]. Activation
of innate immunity is associated with a reduction in effi-
cacy of gene delivery [11,23]. It may further cause
significant inflammatory reactions leading to morbidity
and mortality of the transduced host [21,22].
Newer generations of helper-dependent, gutted adeno-
viral vectors or adeno-associated viruses, which are
depleted of almost all viral coding sequences [24], cause
diminished adaptive immune responses to these vectors
and improve the duration of gene transfer [25]. How-
ever, acute toxicity and diminished vector persistence
provoked by the innate immune response remain the
most significant barriers to clinical application of this
promising technology [26]. To improve safety, efficacy
and duration of adenoviral gene transfer it is necessary
to explore the mechanisms by which adenoviruses trig-
ger the innate immune response.
The detection of microbial components by pattern
recognition receptors (PRRs) is one of the earliest defense
mechanisms that is known to trigger innate immune
responses against infections [27,28]. Of the many classes
of molecules detected by cells as pathogen associated
molecular patterns (PAMPs), nucleic acids are potent
and broadly recognised [29-35]. To sense nucleic acids
the immune system employs several classes of receptors,
including RNA helicases that can respond to cytosolic
ribonucleic acid (RNA) and DNA under certain condi-
tions (retinoic acid-inducible gene I (RIG-I)/melanoma
differentiation associated gene 5 (mda5) [35-37]), and
Toll-like receptors (TLRs) that can recognise endosomal
dsRNA (TLR-3) [38], singlestranded (ss)RNA (TLR-7/-8)
[39-41], and hypomethylated DNA (TLR-9) [42].
Activation of TLRs occurs on the cell membrane sur-
face (TLR-1, -2, -4, -5, -6 and -11) or within endosomal
compartments (TLR-3, -7 and -9) and requires either a
Myeloid differentiation primary response gene 88
(MyD88) or TIR-domain-containing adapter-inducing
interferon-b (TRIF) adapter molecules [43]. These pro-
teins facilitate activation of downstream signalling cas-
cades, which lead to the activation of inflammatory
transcription factors, including nuclear factor-kappa B
(NFB), activator protein 1 (AP-1) and interferon regu-
latory factors (IRF) [43,44]. The presence of viruses in
cells is detected by TLR-3, -7, -8 and -9. TLR-3 recog-
nises double-stranded (ds) ribonucleic acid (RNA) [45],
TLR-7 and TLR-8 bind single-stranded RNA [46,47],
whereas TLR-9 senses dsDNA which is also contained
in adenoviruses [42].
S i n c et h ed i s c o v e r yo fT L R - 9 ,t h e r eh a sb e e nag r o w -
ing body of evidence that DNA derived from microbial
and host cells can be recognised via a TLR-9-indepen-
dent mechanism. DNA recognition in these pathways is
sequence independent and occurs in the cytoplasm of
the cells [48,49]. Different ligands, such as adenoviral,
mammalian and vertebrate DNA as well as dsDNA have
been characterised for TLR-independent recognition in
antigen presenting cells (APCs) [50-57].
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immune responses has been identified and termed
DNA-dependent activator of IFN-regulatory factors
(DAI and also known as DLM-1 and ZBP1) [58]. Subse-
quent studies have shown the presence of an additional
mechanism(s) for DNA-sensing and activation of the
innate immune system, as well as a mechanism of nega-
tive regulation of cytosolic DNA-mediated immune
responses [59,60]. NACHT-leucine-rich repeat-PYD
containing protein 3 (NALP3) also known as cryopyrin,
and its adaptor protein apoptosis-associated speck-like
protein containing a CARD (ASC), regulate secretion of
interleukin (IL)-1b in response to an adenovirus infec-
tion [61,62]. Inflammasome activation also occurs upon
cytosolic exposure of DNA, though in this case DNA-
sensing was shown to be dependent on ASC and not
NALP3 [61]. It remains unclear, however, as to whether
the NALP3/ASC inflammasome can directly detect cyto-
solic DNA or if the response is triggered by another
protein. Another negative regulator of the DNA-
mediated innate immune response, adenosine deaminase
acting on RNA 1 (ADAR1), has also been reported [60].
ADAR1 is an IFN inducible protein that possesses
DNA-binding domains similar to those found in DAI.
Several studies on (adenoviral) DNA induced innate
immune reaction have focused on antigen presenting
cells (APCs) such as dendritic cells (DCs) or macro-
phages (MF). However, information about innate
immune reactions and mechanisms in virus recognition
in epithelial cells, such as keratinocytes, is very limited.
For optimization of cutaneous gene therapy, it is neces-
sary to investigate the immune reaction of the predomi-
nant epidermal cell type after adenoviral challenge.
Since keratinocytes represent the majority (approx. 90%)
of cells of the outermost epidermal layer [63], the aim
of this study was to investigate the signal transduction
of the innate immunity after adenoviral DNA internali-
zation in this specific cell type. In addition, systemic
effects of adenovirally induced immune reactions will be
studied.
Results
DNA internalization induced innate immune reaction
In order to get a deeper insight into the molecular
mechanisms of the innate immune system after (adeno-
viral) DNA internalization into keratinocytes, we
decided to use a GFP-encoding adenovirus for this
study. Since this generation of adenoviral vectors exhibit
a high immunogenicity, this vector seemed to be an
interesting tool for the investigation of signal transduc-
tion moleculess involved in adenovirus detection.
The basal mRNA levels of 18S ribosomal RNA, type-I-
interferons and cytokines (IL-1a, IL-6, IL-8 and TNF-a)
possessed a comparable profile in HaCaT cells HKC
(Figure 1A). HKC possessed significant higher levels of
IL-1a (20-fold, p = 0.014) and IL-8 (5-fold, p = 0.002)
mRNA compared to HaCaT cells. In contrast, mRNA
level of IL-6 was detected on a significant higher level in
HaCaT cells (3.7-fold, p = 0.045).
In order to get any information whether cytoplasmatic
localised adenoviral DNA is capable to induce an innate
immune reaction, human keratinocytes were transfected
with DNA. Adenoviral DNA internalization led to a sig-
nificantly increased (p = 0.007) IFN-a expression 12 h
post transfection in HaCaT cells. The same cells demon-
strated a significant increase in IFN-b expression
(700-fold at stimulation with 3 μgD N A / m lm e d i u m ,
p = 0.002) after stimulation for 15 h (Figure 1B).
Besides type-I-IFN expression, there was significant
increase in expression of inflammatory cytokines,
namely interleukin (IL)-1, IL-6, IL-8 and TNF-a
recorded in HaCaT cells and HKC with a maximal
induction 24 h (HaCaT) and 12 - 24 h (HKC) post
transfection (Figure 1B).
After detection of an adenoviral DNA induced inflam-
matory response in human keratinocytes it was interest-
ing to see whether DNA from other species is also
capable to activate an inflammatory reaction in these
cells. RT-PCR analysis showed an increased induction of
IFN-a in both cell types after S. cerevisiae (SC-) and
Ad-DNA treatment (Figure 1C). Maximal induction of
IFN-a after treatment with SC-DNA was 4.8-fold in
HaCaT cells and 2-fold in HKC. Transfection of calf
thymus (CT-) and plasmid (P-) DNA did not show any
significant effect in either cell type. The transfection
w i t hS C - D N Al e dt oas i g n i f i c a n ti n c r e a s e( p<0 . 0 5 )o f
IFN-b in both cell types. In HaCaT cells, a 2380-fold
upregulation was detected (p = 0.001) whereas HKC
accounted for a 11-fold increase of transcription (p =
0.007). Ad-DNA stimulation of both cell types also
induced an expression of IFN-b in keratinocytes (94-
fold in HaCaT cells; 1.6-fold in HKC). No changes in
IFN-b expression of both cell types were demonstrated
post CT-DNA stimulation and P-DNA induced upregu-
lation of IFN-b was only detected in the HaCaT cell line
(8-fold change; p = 0.012).
In order to get any information about the innate
immune reaction after adenoviral transduction, HaCaT
cells were transduced with different concentrations of
adenoviral vectors (10
8 -1 0
10 infection units (IU) of the
GFP-encoding adenoviral vector (Figure 1D). A concen-
tration dependent induction of IFN-a and IFN-b was
observed 15 h post transduction (IFN-a:2 . 6 - f o l d( 1 0
8
IU, p = 0.056), 7-fold (10
9 IU, p = 0.02), 11.8-fold (10
10
I U ,p=0 . 1 6 4 ) ;I F N - b:2 - f o l d( 1 0
8 IU, p = 0.171),
4.2-fold (10
9 IU, p = 0.046), 17.3-fold (10
10 IU, p = 0.0156).
An adenoviral transduction of human ex vivo full
skin samples led to an induction of IFN-a (11-fold;
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0.167); IL-6 (9-fold; p = 0.001); IL-8 (13-fold; p = 0.076)
and TNF-a (10-fold; p = 0.133) (Figure 1E).
Involvement of Toll-like receptor family in DNA
recognition
Toll-like receptors (TLR) are among the most important
receptor of innate immunity. For an investigation of the
involvement of TLRs in adenoviral DNA detection. The
expression levels of TLR-2, -7 and -9 were determined
after transfection of DNA from different species. There
was no significant change in expression of TLR-2, -7, -9
and TRIF in both cell types (Figure 2). An increased
amount of MyD88 mRNA was detected in HaCaT cells
stimulated with SC-DNA (4.2-fold; p = 0.057), Ad-DNA
(3.8-fold; p = 0.041) and P-DNA (1.6-fold; p = 0.001).
Figure 1 DNA internalization induced innate immune reaction. (A) RT-PCR analysis of type-I-interferon and cytokine basal expression in
untreated HaCaT cells and HKC. (B) RT-PCR analysis of type-I-interferon and cytokine expression in HaCaT cells and HKC stimulated with different
doses of adenoviral DNA (1, 3 and 5 μg DNA/ml medium) for 3 to 24 h. Results were normalized to a vehicle control (Fugene alone) (^ = p <
0.05, ^^ = p < 0.005 (1 μg DNA/ml medium);/= p < 0.05,//= p < 0.005 (3 μg DNA/ml medium); + = p < 0.05, ++ = p < 0.005 (5 μg DNA/ml
medium). Data was presented as mean ± SEM (n = 3 per group). (C) RT-PCR analysis of type-I-interferon expression in HaCaT cells and HKC
stimulated with DNA (5 μg DNA/ml medium) from adenovirus (Ad), Saccharomyces cerevisiae (SC), calf thymus (CT) and plasmids (P). Cell were
stimulated for 6 h (HKC) and 15 h (HaCaT cells). Results were normalized to a vehicle control (Fugene alone). Data was presented as mean ±
SEM (n = 3 per group), * = p < 0.05). (D) RT-PCR analysis of type-I-interferon of HaCaT cells transduced with different concentrations of
adenovirus (10
8 -1 0
10 IU; * = p < 0.05). (E) RT-PCR analysis of type-I-interferon and cytokine induction in human full thickness skin 12 h after
injection of 10
10 IU of an adenoviral type 5 vector encoding for the green fluorescent protein (GFP) (* = p < 0.05). Results were normalised to
18S ribosomal RNA (ratio: target gene/housekeeping gene) and compared to non-treated samples (vehicle control).
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HKC cells stimulated with SC-DNA (1.6-fold; p = 0.03)
and Ad-DNA (1.2-fold; p = 0.3). Stimulation of HaCaT
cells and HKC with CT-DNA and P-DNA stimulation
of HKC did not show any significant differences.
A transfection of HaCaT cells with Ad- and SC-DNA
led to an induction of DAI. Transfection with Ad-DNA
led to a 4.3-fold (HaCaT, p = 0.15) and 2.79-fold (HKC,
p = 0.059) increase of DAI mRNA. Moreover, treatment
of the cells with SC-DNA resulted in a stronger induc-
tion of DAI (6.4-fold (HaCaT, p = 0.087), 9.1-fold
(HKC, p = 0.13)).
DNA recognition and signal transduction
To get a deeper indight into signal transduction
mechanisms after adenoviral challenge, different signal
transduction molecules (namely NFB, ERK2, MAPKK,
p38 MAPK, JAK/STAT, JNK and PI3K were inhibited
and the IFN expression was compared. Results shown in
Figure 3 were normalised to the vehicle control. The
IFN-a/b regulation in non-inhibited positive controls
was comparable to previous experiments (Figure 1). The
HaCaT cells and HKC demonstrated involvement of the
same signal transduction pathways for IFN-a/b produc-
tion (Figure 3), except for the expression of IFN-a in
HKC, which did not show any significant regulation of
Figure 2 Involvement of Toll-like receptor family in DNA
recognition. RT-PCR analysis (45 cycles) for TLR-2, -7, -9, TRIF and
MyD88 and DAI expression in HaCaT cells and HKC stimulated with
DNA (5 μg DNA/ml medium) from adenovirus (Ad), Saccharomyces
cerevisiae (SC), calf thymus (CT) and plasmids (P). Cells were
stimulated for 6 h (HKC) and 15 h (HaCaT cells). Data from DAI
expression was generated from cells transfected with 5 μg DNA/ml
medium. Results were normalised to 18S ribosomal RNA (ratio: target
gene/housekeeping gene) and compared to non-treated samples
(vehicle control) (* = p < 0.05; ** = p < 0.005 to vehicle control).
Figure 3 DNA recognition and signal transduction.R T - P C R
analysis of type-I-interferon expression in HaCaT cells and HKC after
preincubation with 10 μMo fN F B-, Erk2/MAPKK-, JAK/STAT-, JNK-,
p38 MAPK- and PI3K-inhibitors (Sigma, Steinheim, Germany) for 1 h
and stimulation with 5 μg S. cerevisiae DNA/ml medium for 6 h
(HKC) and 15 h (HaCaT cells). The results were normalised to 18S
ribosomal RNA (ratio: target gene/housekeeping gene) and
compared to non-treated samples (vehicle control) (* = p < 0.05;
** = p < 0.005 to positive control (SC-DNA transfected, non-
inhibited); # = p < 0.05; ## = p < 0.005 to vehicle control).
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ment of p38 MAPK, PI3K, JNK and NFBi nt r i g g e r i n g
IFN-a/b production as the mRNA expression ratio was
significantly decreased to a maximum difference of 27%
compared to non-inhibited positive controls. Samples
treated with Erk2/MAPKK and JAK/STAT inhibitors
showed significantly reduced IFN-a/b expression from
46 to 56% compared to the positive control (Figure 3).
IFN-a mRNA levels of p38 MAPK-inhibited samples
were significantly different compared to the non-inhib-
ited positive control (p = 0.002) in HaCaT cells. The
lowest signals in IFN-b expression were obtained in
PI3K inhibited samples (13% in HaCaT cells (p = 0.05)
and 18% in HKC (p = 0.01) compared to positive
control and JNK blocked HKC (14%, p = 0.002).
Investigation of adenovirus induced immune reaction
in vivo
In vitro cell culture assays are not convenient for an
investigation of systemic inflammatory effects after ade-
n o v i r a lc h a l l e n g e .T og e ts o m ei n f o r m a t i o na b o u tt h e
systemic influences on vector reapplication, in vivo stu-
dies have been performed. In these experiments, immu-
nocompetent (SKH-1
h/r) and T-cell deficient athymic
(Foxn-1
nu) mice were twice transduced with the Ad-
GFP vector. The transgene expression and inflammatory
response was measured via life imaging and qRT-PCR.
An application of 10
10 IU Ad-GFP into immunocom-
petent mice resulted in a GFP expression detectable for
9 days with a maximum at day 2 (1,25 × 10
9 relative
light units (RLU); Figure 4). A second injection of the
same vector dose (AdV+AdV) as well as first transduc-
tion of two new areas (PBS+AdV) on day 14 led to an
increased GFP expression for 5 days with a maximum of
2,4 × 10
4 RLU (AdV+AdV; p = 0.007) and 2 × 10
10 RLU
(PBS+AdV; p = 0.007) after 24 h. An application of 10
10
IU AdGFP into athymic mice resulted in a GFP expres-
sion of 4 × 10
8 RLU two days post transduction. The
expression level was reduced to 6 × 10
3 RLU five days
post transduction and stayed on a relatively constant
level until the end of the experiment on day 19 (p <
0.005). A second injection of the same vector dose into
the same area did not show any changes in GFP expres-
sion. A transduction of the PBS treated (day 0) areas on
day 14 resulted in an induction of GFP synthesis con-
verging a level of 7.5 × 10
4 RLU after 24 h. No signifi-
cant changes were measured at the following time
points until the end of the experiment at day 19.
In addition to transduction with 10
10 IU AdGFP, two
other virus concentrations of 10
8 IU and 10
9 IU were
also tested for intradermal transduction of SKH-1
h/r
mice. The application of 10
8 IU Ad-GFP did not show
any detectable effects whereas the application 10
9 IU
AdGFP lead to a GFP expression over a period of
7 days with a maximum of 1820 RLU on day 6 (p =
0.082). A reapplication of the same vector dose did not
show any effect (Figure 5A). In contrast, the application
of 10
10 IU Ad-GFP resulted in a GFP expression for
12 days with maximum at day 2 (5663 RLU, p = 0.094;
Figure 5A). Reapplication of the same doses of Ad-GFP
on day 14 and 28 reduced GFP expression [69% (p =
0.158) and 27% (p = 0.236) of expression on day 2] and
duration (5 days; Figure 4). Blood count analysis showed
a constant increase in numbers of leukocytes, granulo-
cytes, lymphocytes and monocytes after application of
10
10 IU Ad-GFP; there were no significant differences
after application of lower doses (Figure 5B). RT-PCR
analysis of type-I-interferon expression after transduc-
tion of athymic and immunocompetent mice exhibited a
lower expression of IFN-a (101-fold, p = 0.02 (SKH-1
h/
r); 1.8-fold, p = 0.09 (Foxn-1
nu)) and IFN-b (47-fold, p =
0.1 (SKH-1
h/r); 1.6-fold, p = 0.08 (Foxn-1
nu)) in athymic
compared to immunocompetent mice (Figure 5C).
Additionally, the expression of other transcripts
encoded by the adenoviral vector, was determined in
this study. The viral early regions E3 and E4 are parts of
the viral genome, possessing major regulatory functions.
While, there was a strong decrease in GFP mRNA level
in immunocompetent mice 48 h after second adminis-
tration of the adenoviral vector, the viral early regions
E3 and E4 showed an increasing expression for 120 h
(Figure 6).
Discussion
There are a number of studies that examine molecular
mechanisms of innate immunity in mice, primates and
humans [11,21-23,64]. However, these studies have a
propensity to only address specialised antigen-presenting
c e l l s( A P C s )s u c ha sD C so rM F [54,57] and RNA
virus-induced immune reactions of APC [46,65,66]. In
addition, data on the role of keratinocytes in innate
immunity, particularly towards DNA internalization and
DNA virus infection is limited. For optimization of a
cutaneous gene delivery, it is critical to shed light on
the molecular mechanisms a signalling pathways of the
immunity of keratinocytes as they protect the body from
the external environment. To address these issues, we
have investigated the molecular mechanisms and signal
transduction molecules involved in innate immunity
towards DNA internalization into human keratinocytes.
This study was performed using a replication incompe-
tent, GFP-encoding adenovirus in order to significantly
induce an innate immune response for an investigation
of signal transduction molecules involved in adenovirus
recognition.
This HaCaT cell line was used as it is simple to culti-
vate and experiments may be carried out under highly
standardised and reproducible conditions [67]. Unlike
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primary keratinocyte under many experimental condi-
tions [68]. The spontaneously immortalised human kera-
tinocyte HaCaT cell line shows almost normal
differentiation and keratinization in skin models [69]
and was used throughout all experiments in comparison
to primary keratinocytes.
To investigate differences between the HaCaT cell line
and primary keratinocytes, this study examined the
innate immune reaction after DNA stimulation. The
Figure 4 Investigation of adenovirus induced transgene expression in vivo. Qualitative GFP fluorescence (relative light units; RLU) detection
of immunocompetent (SKH-1
h/r (A)) and athymic (Foxn-1
nu (B)), hairless mice at timepoints 2 - 19 days after intradermal injection of 10
10 IU Ad-
GFP at day 0 and reinjection of the same areas and transduction of a third area on day 14 (* = p < 0.05, + = p < 0.005 (AdV+AdV); - = p <
0.005 (PBS+AdV)). (C) Quantitative (RLU) GFP-fluorescence detection of an athymic (Foxn-1
nu) and immunocompetent mice (SKH-1
h/r)a t
timepoints 2 - 19 days after intradermal injection of 10
10 IU Ad-GFP at day 0 and reinjection of the same areas and transduction of two new
areas on day 14.
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the investigation of innate immune responses. Cytokine
expression in HaCaT displayed expected differences in
comparison to HKC, but consistent with Köllisch et al.,
results were broadly comparable in chronology of inter-
feron and cytokine induction at both cell types [70].
Any differences of induction intensity and kinetics
between HaCaT cells and HKC were not unexpected
due to altered growth conditions and the high number
of passages of HaCaT cultures. Both cell types exhibit
the same time-course with a primary induction of IFN-
a ( H a C a T :1 2h ;H K C :3h ) ,f o l l o w e db ya ni n c r e a s e d
IFN-b expression (HaCaT: 15 h; HKC: 6 h) and cytokine
expression (HaCaT: 24 h; HKC: 12 - 24 h).
Transduction of ex vivo full skin samples with an adeno-
viral vector also led to an induction of inflammatory med-
iators. This induction was measured on a comparable level
to primary keratinocytes in vitro. This issue confirms the
validity of data obtained in in vitro experiments with HKC.
Studies have described an activation of innate immu-
nity independent of the species and sequence of interna-
lised DNA, only the presence of nucleic acid in the
cytoplasm elicits an immune reaction. The induction of
type-I-interferon and cytokine synthesis during
Figure 5 Investigation of adenovirus induced immune reaction in vivo. (A) Quantitative GFP fluorescence and (B) numbers of leucocytes
(WBC), granulocytes (GRA), lymphocytes (LYM) and monocytes (MO) in immunocompetent, hairless mice (SKH-1
h/r) at timepoints of 14, 28 and
42 days after intradermal injection of 10
8 -1 0
10 IU Ad-GFP. (C) RT-PCR analysis of IFN-a and IFN-b expression 48 h after intradermal injection of
10
10 IU Ad-GFP in immunocompetent (SKH) and athymic (Foxn) mice. Results were normalised to an untreated control area.
Figure 6 Adenoviral mRNA-expression in vivo. RT-PCR analysis of
viral regions E3, E4 and transgene GFP expression in
immunocompetent mice up to 120 h post transduction with 10
10
IU Ad-GFP (* = p < 0.05, ** = p < 0.005). Data was normalised to
18S ribosomal RNA (ratio: target gene/housekeeping gene).
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has been shown by different groups [48,53,55,56,71].
Limited data regarding immunogenicity of epidermal
cells to different species of DNA is available. There is
evidence for species independent induction of innate
immunity when DNA is localised in the cytoplasm of a
cell [48,49] and immune induction via cytoplasmatic
localised mammalian DNA has been demonstrated espe-
cially by an organism’s individual DNA [53,55,56,71].
This study demonstrates a high induction of type-I-IFN
by (adenoviral) DNA internalization. The results suggest
that cytoplasmic localised DNA triggers induction of
type-I-interferon in HaCaT cells and HKC. In contrast to
Shirota et al., we did not find any immune reaction after
stimulation with DNA from calf thymus (CT) which does
not support the hypothesis of immune induction through
mammalian DNA [55]. For APC, Shirota et al.s h o w e d
an 800-fold induction (DCs) and a 200-fold induction
(MF)o fI F N - b in consequence of CT-DNA internaliza-
tion [55]. In contrast to mammalian DNA, fungal DNA
stimulation led to a significantly increased expression of
type-I-IFN as well as adenoviral DNA. Taken together,
the results of the present study indicate an important
role of keratinocytes in innate immunity. Keratinocytes
may not recognise pathogens in the same manner as
APCs, but the data proposes a major role of keratinocytes
in innate immune defense against pathogens.
However, once induction of innate immunity by trans-
fection of (adenoviral) DNA was demonstrated, this
study investigated signal transduction pathways involved
in DNA recognition. The Toll-like receptor family is the
best known PRR with TLR-9 being the unique dsDNA
detection receptor for this family [43]. Downstream sig-
nalling in TLR pathways is dependent on the adapter
molecules MyD88 and TRIF [72]. Studies investigating
DNA/RNA recognition in different cell types propose
TLR-dependent and -independent pathways for DNA/
RNA recognition in APCs [43,50,54,56,57]. There is lim-
ited data regarding molecular mechanisms of pathogen
recognition in keratinocytes, so the involvement of
TLR-9 and the adapter molecules for TLR signalling
(MyD88 and TRIF) was investigated. The results indi-
cate TLR-9 and TRIF-independent recognition of
dsDNA in HaCaT cells and HKC. Interestingly, both
cell types exhibit an upregulation of MyD88 after DNA
internalization, which may denote involvement of other
TLR receptors [73].
In addition to DNA recognition via TLR-9, there is
also a possibility of RNA transcript or another pathogen
associated molecular patterns (like zymosan, a polysac-
charide from S. cerevisiae) induced TLR pathway induc-
tion. Therefore, this study investigated the induction of
TLR-7 (viral RNA sensing receptor) and TLR-2 (zymo-
san detecting receptor). Evidence supports a RNA
transcript and zymosan independent immune induction,
since there were no changes in expression of these
receptors detected. In contrast, and induction of DNA
recognising receptor DAI was observed in both cell
types, indicating a TLR-independent DNA recognition
in keratinocytes.
Besides involvement of TLR receptor pathways in
DNA recognition, this study examined participation of
different effector molecules in cytokine induction. Inhi-
bitor studies in HaCaT cell and HKC showed a ‘two-
step’ inhibition in both cell types. On the one hand, an
interferon down-regulation of 38 to 54% compared to a
non-inhibited positive control was detected in conse-
quence of blocking Erk2/MAPKK- and JAK/STAT-regu-
lated pathways. On the other hand, inhibition of NFB-,
JNK-, p38 MAPK- and PI3K-regulated pathways led to a
maximal IFN down-regulation of 25% compared to non-
inhibited positive control. These results suggest a major
participation of NFB, JNK, p38 MAPK and PI3K and
also an involvement of Erk2/MAPKK and JAK/STAT in
signal transduction after recognition of cytoplasmatic
localised DNA. PI3K-mediated signal transduction plays
a major role in IFN induction in keratinocytes. In agree-
ment with the present study, Philpott et al. described a
PI3K-mediated TNF-a induction pathway [74]. A major
involvement of JNK, p38 MAPK and NFBi nI F N -
induction was not unexpected as these factors play a
crucial role in initialization of transcription which is
mediated by different pathways like TLR-, PI3K- JAK/
STAT and MAPK-cascades [75]. Secondary involvement
of Erk2/MAPKK- and JAK/STAT-regulated pathways
may be due to a feedback mechanism mediated by cyto-
kine receptors in the cells. The results suggest that
induction of these pathways by cytokines may be pri-
marily initiated by DNA recognition involving PI3K-
dependent signalling cascades.
The data for dose-dependence between vector dose
and immune reaction for in vivo adenoviral gene deliv-
ery is supported by other studies [54,55,57]. The results
demonstrate that local and systemic immune reactions
led to increased counts of leukocytes, lymphocytes,
monocytes and granulocytes in mice.
T h ep r e s e n ts t u d ye x h i b i t sac o m p a r a b l et i m ec o u r s e
in GFP expression post reapplication of the identical
vector dose into the same or non-transduced areas.
These results suggest not only a local but also a sys-
temic reaction against adenovirus, leading to decreased
intensity and duration of transgene expression. Hence,
therapeutic reapplication of the vector to stabilise
transgene expression may be hindered [54,57]. Adeno-
viral in vivo transduction into athymic mice, which exhi-
bit a deficient T-cell system and hence a reduced
adaptive immune response, led to a stable transgene
expression and reapplication of same vector doses into
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expression to the same level of areas of primary applica-
tion. This, taken together with a diminished expression
of type-I-interferon and proinflammatory cytokines,
implies potential for effective adenoviral gene delivery
into immunosuppressed skin and a future direction of
our study may be to investigate inhibition of factors like
type-I-interferons in order to optimise gene therapy
with adenoviruses. Interestingly, there was a decrease in
GFP mRNA level detected together with an increasing
amount of viral region E3 and E4 mRNA (also encoded
by the adenoviral vector), suggesting a gene silencing
mechanism to regulate transgene expression in the tis-
sue. Since this mechanism could not be explained yet,
subsequent experiments are needed to analyse mRNA
regulating effects.
The results of this study suggest an induction of the
innate immunity triggered by cytoplasma localised DNA
which is mediated by PI3K-, p38 MAPK-, JNK-, NFB-,
JAK/STAT- and ERK1/2-dependent pathways. After
vector reapplication in vivo, immnocompetent mice pos-
sessed a decrease in duration and intensity in transgene
expression. A stable transgene expression and a reduced
inflammatory response in immunodeficient mice have
been observed, suggesting opportunities for a higher
efficiency of cutaneous gene delivery in immunosup-
pressed skin. It might be an interesting approach to
influence in signal transduction cascades for an optimi-
zation of cutaneous gene delivery. Therefore, it is
important to constitute any pathogen recognition recep-
tors involved in recognition of adenoviral vectors. Since
t h ep r e s e n ts t u d yd i dn o to b s e r v ea n yi n d u c t i o no f
TLRs 2, 7 and 9, but an induction of DAI, there is evi-
dence for a TLR independent DNA recognition pathway
in human keratinocytes. Further investigation will be
required to fully describe and understand the complex
mechanism in signal transduction after adenoviral chal-
lenge in human epidermal cells.
Conclusion
In summary, the results of this study suggest an TLR-
independent induction of the innate immunity triggered
by cytoplasm localised DNA which is mediated by PI3K-,
p38 MAPK-, JNK-, NFB-, JAK/STAT- and ERK1/2-
dependent pathways in human keratinocytes. This activa-
tion of innate immunity leads to a decrease in intensity
and duration of adenovirally induced transgene expres-
sion. In contrast, a stable transgene expression and a
reduced inflammatory response have been observed in
immunodeficient mice. These results provide potential
for an effective adenoviral gene delivery into immunosu-
pressed skin.
Methods
Keratinocyte cell culture
Fresh human skin was obtained after abdominoplasty sur-
gery (informed consent was given by the patient) and
washed in PBS (PAA Laboratories, Coelbe, Germany). The
skin was placed in a sterile petri dish and the hypodermis
was excised. The skin was disinfected with Lavasept
®
(Braun AG, Melsungen, Germany) for 5 min and washed
with PBS, the tissue was sliced into pieces of 1 cm
2. Skin
pieces were transferred into a new petri dish with the epi-
dermal side up and the skin was completely immersed
with freshly prepared 0.2% dispase-solution (4.7 U/ml,
Gibco, Paisley, United Kingdom [UK]) and incubated
overnight at 4°C. The epidermis was peeled off and placed
in Trypsin/EDTA-solution (0.05%/0.02%, Gibco, Paisley,
UK) and reduced to pieces as small as possible. The pieces
were incubated at 37°C for 20 min in a gently shaking
(180 rpm) waterbath (GFL Burgwedel, Germany). The cell
suspension was vortexed and the trypsin digestion was
stopped by adding fetal bovine serum (FBS, HyClone,
Logan, USA). The suspension was filtered through a 100
μm cell strainer (Becton Dickinson Heidelberg, Germany)
and centrifuged at 400 × g, 20°C for 5 min. The cells were
resuspended in a 5 ml keratinocyte medium (containing
3:1 Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
Paisley, UK), Ham’s F12 (Gibco, Paisley, UK), 10% FBS
(Hyclone, Logan, USA), 1% Penicillin/Streptomycin (ICN,
Aurora, USA), 4 mM L-Glutamin (ICN, Aurora, USA),
24.3 μg/ml Adenine (Calbiochem, Darmstadt, Germany),
5 μg/ml Insulin (Sigma, St. Louis, USA), 0.8 μg/ml Hydro-
cortisone (Calbiochem, Darmstadt, Germany), 1.346 ng/ml
Triiodothyronine (Sigma, St. Louis, USA), 10
-6 M Isopro-
terenol (Sigma, St. Louis, USA), 20 ng/ml hEGF (Sigma,
St. Louis, USA) and counted by CASY
®-1 (Schärfe-System,
Reutlingen, Germany). Cells were seeded at a density of
75,000 cells/cm
2 into collagen type I (Becton Dickinson
Falcon, Heidelberg, Germany) precoated culture flasks. All
different cell types including HaCaT (kindly provided by
Prof. Fusenig, University of Heidelberg) cell lines were cul-
t u r e da t3 7 ° Ci nh u m i d i f i e da t m o s p h e r eo f5 %C O 2.
HaCaT cells were cultured in DMEM containing 10% FBS
(Hyclone, Logan, USA) and 1% Penicillin/Streptomycin,
medium was changed every second day.
Human full skin culture
Fresh, sterile human skin explants were obtained from
three adult healthy patients (age range: 19-43 years)
undergoing abdominoplasty surgery. The study was
approved by the local ethics committee, and all of the
patients gave written informed consent.
Immediately post excision, the skin was additionally
washed in antiseptic (Octenisept, Schuelke-Mayr,
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three times in phosphate buffered saline (PBS). Subcuta-
neous fat was excised and the tissue was sliced into
equilateral triangular pieces with sides of 2.5 cm length.
These pieces were transferred to the base of a stainless
steel chamber [76], placing the epithelial site upward.
The upper part of the chamber was bolt down until the
tissue was fixed, and during fixation, the skin explants
were stretched to prevent contraction. Samples were
cultured at the air-liquid interphase by using a 6-well
plate filled with 5 ml of culture medium; DMEM, con-
taining 10% FBS, 1% penicillin/streptomycin, and
amphotericin B (25 μg / m L ,P A A ,P a s c h i n g ,A u s t r i a ) .
The tissue was incubated at 37°C in a humidified atmo-
sphere containing 5% CO2, and the medium was chan-
ged twice a week.
Skin explants were prepared and cultured for at least 1
week. 10
10 IU Ad-GFP (green fluorescent protein) in 50
μl PBS were intradermally injected. After 12 h (nPBS =3 ,
nAd-GFP = 3 samples per group; 3 patients per group),
tissue biopsy specimens were harvested for total RNA
isolation.
Production and purification of recombinant adenovirus
In these studies, replication-deficient human ΔE1 adeno-
viruses type 5 (Ad5) with inserted cytomegalovirus
(CMV)-promoter driven green fluorescent protein (GFP)
was used. This virus exhibits a replacement of viral early
E1 gene, which is essential for viral replication, with
DNA material encoding for the green fluorescent pro-
tein (GFP). The virus was propagated in HER911 cells
(DMEM containing 10% FBS and 1% P/S), purified by
two sequential cesium chloride (CsCl2) gradients, and
dialysed against 20 mM Tris/HCl, pH 8.0. The titer was
determined using an Adeno-X™ r a p i dt i t e rk i t( B e c t o n
Dickinson Bioscience, K1653-1, Heidelberg, Germany).
Virus stocks (2.11*10
11 infection units (IU)/ml) were
stored at -80°C. Therefore, 10% glycerol was admixed.
DNA purification
Adenoviral (Ad5) and bacterial (plasmid; P) DNA was
purified using QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) following the manufacturer’si n s t r u c t i o n sf o r
blood and body fluid. For purification of DNA from Sac-
charomyces cerevisiae (SC-DNA) (Deutsche Hefewerke,
Nürnberg, Germany), 2 mg of cells were ground in a
liquid nitrogen filled mortar. After cell disruption, 200 μl
buffer ATL and 25 μl Proteinase K (Qiagen, Hilden,
Germany) were added. The next steps were performed
according to the manufacturer’s instruction. The purified
DNA was eluted in a final volume of 200 μlD N a s e - f r e e
H2O and the concentration was photometrically deter-
mined (Eppendorf Biophotometer, Hamburg, Germany)
a n ds t o r e da t- 8 0 ° Cu n t i lu s a g e .D N As a m p l e sw e r e
tested for contaminations via optical density (OD) ratio
of 260 nm and 280 nm; DNA samples used for transfec-
tion showeded an OD ratio of >1.8. Calf thymus DNA
was purchased from Sigma (Sigma, Taufkirchen, Ger-
many) and bacterial plasmid DNA was purchased from
Clontech (BD Biosciences Clontech, Heidelberg,
Germany).
Transfection
Cells were grown in 6-well plates until 90-100% con-
fluency. DNA transfection complexes were prepared
according to the manufacturer’si n s t r u c t i o n s( R o c h e
Molecular Biochemicals, Mannheim, Germany). Briefly,
DNA was mixed 2:5 with the Fugene
® HD transfection
reagent (Roche Molecular Biochemicals, Mannheim,
Germany) in PCR-grade water (Roche Molecular Bio-
chemicals, Mannheim, Germany) for 15 min at room
temperature and then added to cells. Negative controls
(vehicle controls) were treated with Fugene
® HD alone
without DNA. Using this agent, a transfection efficiency
of 22.4% (HaCaT cells) or 17.4% (HKC) has been
reached using adenoviral DNA. If not mentioned other-
wise, transfection experiments were performed in tripli-
cate for each group.
RNA isolation and analysis
Cultured cells were lysed directly with buffer RLT
(Qiagen, Hilden, Germany) containing 1% (v/v) ß-
Mercaptoethanol (Sigma, Taufkirchen, Germany). Isola-
tion of total RNA was done using the RNeasy Mini Kit
(Qiagen, Hilden, Germany), following the manufacturer’s
instructions for animal cells including DNA-digestion
(RNase-free DNase Set, Qiagen, Hilden, Germany). Skin
tissue has been taken and weighed in order not to
exceed 30 mg. Tissue was stored at -80°C in RNAlater
until further processing. Isolation of total RNA was
done using the RNeasy Mini Kit, following the manufac-
turer’s instructions for isolation of total RNA from
heart, muscle and skin including DNA-digestion
(RNase-free DNase Set, Qiagen, Hilden, Germany). RNA
was eluted in a final volume of 30 μlR N a s e - f r e eH 2O.
The concentration of RNA was determined using the
Eppendorf Biophotometer (Eppendorf, Hamburg,
Germany).
Reverse Transcription
For transcription of RNA into DNA (reverse transcrip-
tion) used for gene expression analysis via polymerase
chain reaction (PCR), 1 μg of total RNA was transcribed
into cDNA using the SuperScript™ II First Strand
Synthesis System for RT-PCR (Invitrogen, Karlsruhe,
Germany), following the manufacturer’si n s t r u c t i o n sf o r
first-strand synthesis using random hexamer primers.
cDNA was stored at -20°C.
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Relative Quantification of mRNA was performed in a
t w o - s t e pr e a l - t i m eR T - P C Rp r o c e d u r eu s i n gt h ef l u o r -
escent dye SYBR Green I (Light Cycler FastStart DNA
Master SYBR Green I, Roche, Mannheim, Germany)
and a Light Cycler 1.0 (Roche, Mannheim, Germany).
The first step consisted of a RT reaction as described
above, the second step of PCR amplification with spe-
cific primers (bottom). These primer pairs were vali-
dated to generate a single PCR-product. The PCR
reactions were performed with 2 μlo fc D N A ,0 . 5μM
of sense and antisense primers, 3 mM MgCl2 and 2 μl
of FastStart SYBR Green reaction mix in a total
volume of 20 μl. The cycling conditions were as
follows: 95°C for 10 min at a ramp speed of 20°C/sec,
40 cycles (if not described otherwise) consisting of 94°
C for 15 sec at a ramp speed of 20°C/sec, a primer
specific annealing temperature for 10 sec at a ramp
speed of 20°C/sec, 72°C for 10 sec at a ramp speed of
20°C/sec, followed by a melting point analysis: 95°C for
0 sec at a ramp speed of 20°C/sec, 65°C for 15 sec at a
ramp speed of 20°C/sec, 95°C for 0 sec at a ramp
speed of 0.1°C/sec, and finally a cooling phase: 40°C
for 30 sec at a ramp speed of 20°C/sec. mRNA concen-
trations were corrected for 18S rRNA in each sample.
Primer sequences for above mentioned genes are as
follows: 18S sense 5’-gaaactgcgaatggctcattaaa-3’; 18S anti-
sense 5’-cacagttatccaagtaggagagg-3’ (annealing tempera-
ture (AT): 60°C); IFN-a sense 5’-acccacagcctggataacag-3’;
IFN-a antisense 5’-ctctcctcctgcatcacaca-3’ (AT: 60°C);
IFN-b sense 5’-actgcctcaaggacaggatg-3’;I F N - b antisense
5’-agccaggaggttctcaacaa-3’ (AT: 60°C); TLR-9 sense 5’-
ggacctctggtactgcttcca-3’; TLR-9 antisense 5’-aagctcgttgta-
cacccagtct-3’ (AT: 55°C); MyD88 sense 5’-gagcgtttc-
gatgccttcat-3’; MyD88 antisense 5’-cggatcatctcctgcacaaa-3’
(AT: 55°C); TRIF sense 5’-ccagatgcaacctccactgg-3’;T R I F
antisense 5’-ctgttccgatgatgattcc-3’ (AT: 55°C). E3 sense 5’-
cctgaaacacctggtccact-3’ (AT: 56°C); E3 antisense 5’-
ctgggtaaactcccgaatca-3’ (AT: 56°C); E4 sense 5’-tcaggtt-
gattcatcggtca-3’ (AT: 56°C); E4 antisense 5’-cctaggcag-
gagggtttttc-3’ (AT: 56°C); GFP sense 5’-acgtaaac
ggccacaagttc-3’ (AT: 60°C); GFP antisense 5’-aagt-
cgtgctgcttcatgtg-3’ (AT: 60°C), DAI sense 5’-aaagcatggac-
gatttaccg-3’ (AT: 60°C); DAI antisense 5’-a t g a t g t t c c
cgtgtccaat-3’ (AT: 60°C).
Protein inhibition
Prior to transfection, cells were pretreated with specific
inhibitors (10 μMe a c h )f o rN F B( I B-a inhibitor
BAY117082 in DMSO), ERK1/2 (PD98059 in DMSO),
p38 MAPK (SB203580 in DMSO), JNK (JNK II-inhibitor
SP600125 in DMSO), PI3K (LY294002 in DMSO) and
JAK-STAT (AG490 in EtOH) (Sigma, Steinheim,
Germany).
Animal studies
The research protocol described below conformed to
all regulations related to animal use and other German
federal statutes. It was performed in compliance with
the ‘G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l s
associated with the German Animal Welfare Act.
A t h y m i cm i c e( F o x n - 1
nu), which are deficient in T-cell
system and provide a reduced adaptive immune reac-
tion, were obtained from Harlan Winkelmann
(Borchen, Germany) and immunocompetent, hairless
“control” mice (SKH-1
h/r) were obtained from Charles
River (Sulzfeld, Germany) and housed under standard
conditions. In the first experiment, a total of nine
immunocompetent mice were randomised into three
groups with n = 3 mice. Each animal was intradermally
transduced with 10
8 -1 0
10 infectious units (IU) Ad-
GFP (green fluorescent protein) in 50 μlP B Sa tt w o
discrete areas on the back. The transgene expression
was controlled by the CMV promoter for high trans-
gene expression rates. Transgene expression was loca-
lised and quantified every second day via Kodak
Imaging Station 4000 MM (Kodak GmbH, Stuttgart,
Germany). 14 and 28 days after first injection a second
and third virus application was performed into the
same areas and into a non-treated area. Blood samples
were taken from the tail vein prior to virus application
(see table 1).
In the second experiment, eighteen immunocompetent
and eighteen immunodeficient mice (SKH-1
h/r and
Foxn-1
nu) were divided into six groups with n = 3 mice
per group. Four distinct areas measuring 1 cm
2 were
marked on the back of each mouse. On day 0, 10
10 IU
Ad-GFP in 50 μl PBS or PBS alone was intradermally
injected into two areas per mouse, followed by a second
injection of 10
10 IU Ad-GFP into all four areas on day
14. 1, 6, 24, 48, 72 and 120 h after second injection, one
group was euthanised by intrathoracic injection of
0.5 ml T61, the transduced skin areas were excised and
stored in liquid nitrogen for RNA isolation.
Statistical analysis
Differences were analysed for statistical significance with
the Student’s t-test. Error bars represent standard errors
Table 1 Inhibitors used in this study
Bay11-7085 nuclear factor B (NFkB)
PD 98,059 extracellular regulated kinase 2 (Erk2); mitogen-
activated protein kinase kinase (MAPKK)
SB203580 p38 mitogen-activated protein kinase (p38 MAPK)
LY294,002 phosphoinositid-3-kinase (PI3K)
Tyrphostin AG
490
januskinase/signal transductor and aktivator of
transcription (JAK/STAT)
SP600125 c-Jun N-terminal kinase (JNK)
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expression ratio of treated and untreated (vehicle con-
trol) cells (x-fold expression).
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